$ADIL
Adial Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000121390024068262 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.275M
YoY Change 21.69%
% of Gross Profit
Research & Development $1.013M
YoY Change 135.53%
% of Gross Profit
Depreciation & Amortization $140.00
YoY Change -108.48%
% of Gross Profit
Operating Expenses $2.287M
YoY Change 54.82%
Operating Profit -$2.287M
YoY Change 54.82%
Interest Expense -$171.1K
YoY Change -980.44%
% of Operating Profit
Other Income/Expense, Net -$171.1K
YoY Change 426.77%
Pretax Income -$2.458M
YoY Change 62.82%
Income Tax
% Of Pretax Income
Net Earnings -$2.458M
YoY Change -325.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$0.59
COMMON SHARES
Basic Shares Outstanding 6.403M shares 4.233M shares
Diluted Shares Outstanding 4.183M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.288M
YoY Change 169.91%
Cash & Equivalents $3.288M
Short-Term Investments
Other Short-Term Assets $535.4K
YoY Change 485.91%
Inventory
Prepaid Expenses $346.8K
Receivables
Other Receivables
Total Short-Term Assets $3.823M
YoY Change 86.79%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $3.631K
YoY Change
Long-Term Investments $1.122M
YoY Change -35.08%
Other Assets
YoY Change
Total Long-Term Assets $1.125M
YoY Change -35.03%
TOTAL ASSETS
Total Short-Term Assets $3.823M
Total Long-Term Assets $1.125M
Total Assets $4.949M
YoY Change 30.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $316.7K
YoY Change 183.55%
Accrued Expenses $335.2K
YoY Change 3.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $671.9K
YoY Change 45.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $671.9K
Total Long-Term Liabilities $0.00
Total Liabilities $671.9K
YoY Change 45.51%
SHAREHOLDERS EQUITY
Retained Earnings -$77.73M
YoY Change 18.69%
Common Stock $4.292K
YoY Change 258.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.277M
YoY Change
Total Liabilities & Shareholders Equity $4.949M
YoY Change 30.95%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.458M
YoY Change -325.99%
Depreciation, Depletion And Amortization $140.00
YoY Change -108.48%
Cash From Operating Activities -$2.148M
YoY Change 13.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 411.1K
YoY Change 685066.67%
NET CHANGE
Cash From Operating Activities -2.148M
Cash From Investing Activities
Cash From Financing Activities 411.1K
Net Change In Cash -1.737M
YoY Change 58.72%
FREE CASH FLOW
Cash From Operating Activities -$2.148M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.59
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.33
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.50
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.42
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
1.76
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
2.30
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1095190 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1131436 shares
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 adil Inducement Expenses
InducementExpenses
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38323
dei Entity Registrant Name
EntityRegistrantName
ADIAL PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3074668
dei Entity Address Address Line1
EntityAddressAddressLine1
4870 Sadler Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Glen Allen
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23060
dei City Area Code
CityAreaCode
(804)
dei Local Phone Number
LocalPhoneNumber
487-8196
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ADIL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6403381 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3288048 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2827082 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
346754 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
188600 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
371597 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
3823402 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3198679 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3631 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3913 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
1121670 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1534013 usd
CY2024Q2 us-gaap Assets
Assets
4948703 usd
CY2023Q4 us-gaap Assets
Assets
4736605 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
316726 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
103325 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
335156 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
477747 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
671882 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
653076 usd
CY2024Q2 us-gaap Liabilities
Liabilities
671882 usd
CY2023Q4 us-gaap Liabilities
Liabilities
653076 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4293681 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4293681 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1663421 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1663421 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
4292 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1663 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82005259 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
72879738 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77732730 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68797872 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4276821 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4083529 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4948703 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4736605 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1012522 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
429896 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1466800 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
795512 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1274708 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1047499 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2665452 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2950658 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2287230 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1477395 usd
us-gaap Operating Expenses
OperatingExpenses
4132252 usd
us-gaap Operating Expenses
OperatingExpenses
3746170 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2287230 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1477395 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4132252 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3746170 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
51404 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19426 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
74207 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
48318 usd
adil Inducement Expenses
InducementExpenses
-4464427 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-222472 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-412343 usd
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
51901 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
43 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
51901 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171068 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32475 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4802606 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3583 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2458298 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1509870 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8934858 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3749753 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-2458298 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1509870 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-8934858 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3749753 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2597674 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1931721 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2458298 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1087804 usd
us-gaap Net Income Loss
NetIncomeLoss
-8934858 usd
us-gaap Net Income Loss
NetIncomeLoss
-1818032 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.59
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.33
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.5
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.42
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
2.3
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
1.76
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4182760 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1131436 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3568336 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1095190 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4083529 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
177003 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
48987 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3824264 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
4464427 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6476560 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6121650 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
153391 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
48987 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
411091 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2458298 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4276821 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3276494 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
397442 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
62135 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
609613 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2905836 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1439848 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
310263 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
427317 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
51901 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1087804 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3317191 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-8934858 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3749753 usd
us-gaap Share Based Compensation
ShareBasedCompensation
428368 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1197157 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
51901 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
282 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
282 usd
adil Warrant Exercise Inducement Expense
WarrantExerciseInducementExpense
4464427 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-412343 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1690 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
346754 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-182997 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-258072 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-142591 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-638916 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-27942 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-155000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
213401 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-169456 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-24062 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3774389 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3207403 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-985856 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3774389 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4193259 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
800000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
800000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
411091 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
609613 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3824264 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
58 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4235355 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
609671 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
460966 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2783588 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2827082 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4001794 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3288048 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1218206 usd
us-gaap Notes Issued1
NotesIssued1
1727897 usd
adil Reimbursement Receivable In Connection With Sale Of Purnovate
ReimbursementReceivableInConnectionWithSaleOfPurnovate
737276 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3800000 usd
CY2024Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
411000 usd
CY2024Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
411000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires Company management to make estimates and assumptions that affect the amounts of assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results might differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include accruals associated with third party providers supporting clinical trials and income tax asset realization.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4577469 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
733386 shares
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
927000 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1600000 usd
CY2023Q2 adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
-50071 usd
adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
260748 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
114297 usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
455431 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
64226 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
716179 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-64226 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-716179 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
174 usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
174 usd
adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
14000 usd
CY2023Q2 adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
2662074 usd
adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
2662074 usd
CY2023Q2 adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
2661900 usd
adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
2647900 usd
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
2597674 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1931721 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2597674 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1931721 usd
us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Equity Interests
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests
1727897 usd
CY2024Q2 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
283269 usd
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
84281 usd
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
273578 usd
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
421365 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
55762 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
50566 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5816 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5816 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
335156 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
477747 usd
CY2023Q2 us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
3000000 usd
CY2023Q2 us-gaap Additional Collateral Aggregate Fair Value
AdditionalCollateralAggregateFairValue
500000 usd
CY2023Q2 adil Daily Trading Value
DailyTradingValue
2000000 usd
CY2023Q2 adil Weighted Average Price Percentage
WeightedAveragePricePercentage
0.95 pure
us-gaap Other Expenses
OtherExpenses
51901 usd
CY2024Q2 us-gaap Assets Sold Under Agreements To Repurchase Market Value
AssetsSoldUnderAgreementsToRepurchaseMarketValue
4283650 usd
CY2024Q2 us-gaap Preferred Stock Including Additional Paid In Capital Net Of Discount
PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount
77600 usd
adil Fixed Commission Rate
FixedCommissionRate
0.03 pure
CY2024Q1 adil Exercise Price Per Share
ExercisePricePerShare
2.82
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3500000 usd
CY2024Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
1.94
us-gaap Deferred Sales Inducements Amortization Expense
DeferredSalesInducementsAmortizationExpense
4464427 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
500000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1189 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0423 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
232812 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.14
adil Weighted Average Remaining Service Period
WeightedAverageRemainingServicePeriod
P3Y
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
599582 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M23D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202378 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
737580 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
428368 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1197157 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
433 shares
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
58 usd
adil License Fees And Milestone Payments Description
LicenseFeesAndMilestonePaymentsDescription
More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of a New Drug Application by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense itself. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
us-gaap Royalty Expense
RoyaltyExpense
20000 usd
us-gaap Royalty Expense
RoyaltyExpense
20000 usd
CY2018Q2 us-gaap Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage
DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
0.05 pure
CY2018Q2 us-gaap Grants Receivable
GrantsReceivable
1000000 usd
CY2018Q2 adil Percentage Of Amount To Be Paid In Cash
PercentageOfAmountToBePaidInCash
0.50 pure
CY2018Q2 adil Percentage Of Amount To Be Paid In Stock
PercentageOfAmountToBePaidInStock
0.50 pure
adil Annual Fee
AnnualFee
375000 usd
CY2022Q3 adil Annual Fee
AnnualFee
430000 usd
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
56792 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
209250 usd
CY2023Q1 us-gaap Deferred Compensation Arrangement With Individual Distribution Paid
DeferredCompensationArrangementWithIndividualDistributionPaid
22000 usd
us-gaap Other General Expense
OtherGeneralExpense
148500 usd
us-gaap Other General Expense
OtherGeneralExpense
77100 usd
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
1400000 usd
adil Other Payments
OtherPayments
879533 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
346126 usd
adil Additional Expense
AdditionalExpense
903789 usd
adil Cash Payments
CashPayments
557662 usd
CY2024Q2 us-gaap Other Commitment
OtherCommitment
564000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
1.7909
CY2024Q3 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3658230 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 adil Inducement Expenses
InducementExpenses
usd
adil Inducement Expenses
InducementExpenses
usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2024Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
CY2024Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.50
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3568336 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4182760 shares
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
adil Warrant Exercise Inducement Expense
WarrantExerciseInducementExpense
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Notes Issued1
NotesIssued1
usd
adil Reimbursement Receivable In Connection With Sale Of Purnovate
ReimbursementReceivableInConnectionWithSaleOfPurnovate
usd
CY2024Q2 adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
usd
adil Disposal Group Including Discontinued Operation Research And Development Expenses
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
usd
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
usd
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
CY2024Q2 adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
CY2023Q2 adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
adil Disposal Group Including Discontinued Operation Change In Value Of Contingent Liability
DisposalGroupIncludingDiscontinuedOperationChangeInValueOfContingentLiability
usd
CY2024Q2 adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
usd
adil Disposal Group Deferred Gain On Disposal Or Sale
DisposalGroupDeferredGainOnDisposalOrSale
usd
CY2024Q2 adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
usd
adil Disposal Group Including Discontinued Operation Other Income Expenses
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses
usd
CY2024Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
CY2024Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2023Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2024Q2 adil Accrued Clinical Research Organization Services And Clinical Consulting Services Current
AccruedClinicalResearchOrganizationServicesAndClinicalConsultingServicesCurrent
usd
CY2023Q4 adil Accrued Clinical Research Organization Services And Clinical Consulting Services Current
AccruedClinicalResearchOrganizationServicesAndClinicalConsultingServicesCurrent
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001513525

Files In Submission

Name View Source Status
adil-20240630_cal.xml Edgar Link unprocessable
0001213900-24-068262-index-headers.html Edgar Link pending
0001213900-24-068262-index.html Edgar Link pending
0001213900-24-068262.txt Edgar Link pending
0001213900-24-068262-xbrl.zip Edgar Link pending
adil-20240630.xsd Edgar Link pending
ea0210867-10q_adial.htm Edgar Link pending
ea0210867ex31-1_adial.htm Edgar Link pending
ea0210867ex31-2_adial.htm Edgar Link pending
ea0210867ex32-1_adial.htm Edgar Link pending
ea0210867ex32-2_adial.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
adil-20240630_def.xml Edgar Link unprocessable
adil-20240630_lab.xml Edgar Link unprocessable
adil-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0210867-10q_adial_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending